Potassium%252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an essential electrolyte used to treat and prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq daily in 1-2 divided doses. * **Treatment:** 40-100 mEq daily in 2-4 divided doses. Maximum daily dose typically 200 mEq. * *Specific dosing depends on serum potassium levels and clinical context, often guided by local protocol.* * **Intravenous (IV):** * **Treatment of Hypokalemia:** Typically administered as a continuous infusion. * **Mild to moderate hypokalemia (serum K < 3.5 mEq/L):** 10-20 mEq/hour. * **Severe hypokalemia or when rapid correction is needed (serum K < 2.5 mEq/L):** May require higher rates, up to 20-40 mEq/hour, but *requires close cardiac monitoring (ECG) and frequent serum potassium checks*. * **Dilution:** Must be diluted in a compatible IV fluid (e.g., NS, D5W). **NEVER administer as a direct IV push or bolus due to risk of cardiac arrest.** * **Concentration:** Concentration should not exceed 40 mEq/L peripherally or 20 mEq/L centrally for infusion rates > 10 mEq/hour to minimize phlebitis. Higher concentrations may be used in critical care with central venous access and continuous ECG monitoring. * *Maximum infusion rate and total daily dose vary significantly based on patient's potassium level, renal function, and clinical status. Often guided by local protocol and physician order.* ## Pediatric Dosing * **Oral:** * **Maintenance:** 1-2 mEq/kg/day divided into 1-2 doses, not to exceed 100 mEq/day. * **Treatment:** 2-5 mEq/kg/day divided into 2-4 doses, not to exceed 20 mEq/dose or 100 mEq/day. * *Specific dosing depends on age, weight, serum potassium levels, and clinical context.* * **Intravenous (IV):** * **Treatment:** 0.5-1 mEq/kg per dose, infused over 1-3 hours. Maximum infusion rate generally 0.3-0.5 mEq/kg/hour, but can be up to 1 mEq/kg/hour in severe cases with continuous cardiac monitoring. * **Concentration:** Should generally not exceed 40 mEq/L to avoid venous irritation. * *Dosing and rate must be individualized based on serum potassium concentration, renal function, and cardiac status. **Continuous ECG monitoring is mandatory for IV potassium administration in pediatric patients, especially those receiving rapid infusions or with serum K < 2.5 mEq/L.** * ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Monitor potassium levels closely. In severe renal impairment, potassium administration may be contraindicated. ## Contraindications * Hyperkalemia. * Conditions causing generalized cellular damage (e.g., severe burns, extensive trauma), as these can lead to hyperkalemia. * Anuria, oliguria, or renal failure with azotemia. * Untreated adrenal insufficiency. * Certain cardiac conduction abnormalities. ## Adverse Effects * **Most Common:** Nausea, vomiting, diarrhea, abdominal pain (oral). * **Serious:** * **Hyperkalemia:** Symptoms include muscle weakness, fatigue, paresthesias, cardiac arrhythmias (including bradycardia, asystole), hypotension, and cardiac arrest. Risk is increased with renal impairment or rapid administration. * **Venous irritation, phlebitis, extravasation** (IV). * **Esophageal or gastric irritation/perforation** (oral, especially with slow-release formulations or if taken with insufficient fluid). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Increased risk of hyperkalemia. * **NSAIDs:** May decrease potassium excretion, increasing risk of hyperkalemia. * **Digoxin:** Hyperkalemia can increase digoxin toxicity; hypokalemia can decrease it. * **Neuromuscular blocking agents:** Hyperkalemia can potentiate neuromuscular blockade. ## Monitoring * **Serum Potassium Levels:** Frequent monitoring is essential, especially during IV administration, dose adjustments, or in patients with renal impairment. * **Renal function (BUN, creatinine):** To assess excretion capacity. * **ECG:** Particularly for IV potassium, especially at higher infusion rates or concentrations, or in patients with known cardiac abnormalities. * **Signs and symptoms of hypokalemia and hyperkalemia.** * **For oral formulations:** Bowel function. ## Clinical Pearls * Oral potassium supplements should always be taken with sufficient fluid to minimize gastrointestinal irritation and risk of esophageal injury. * IV potassium must be diluted appropriately and infused at recommended rates to prevent cardiac complications. * Consider the source of potassium loss (e.g., diuretics, GI losses) when managing hypokalemia. * Concurrent use of medications that increase potassium levels requires careful monitoring. *** *Disclaimer: This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines. Always verify current drug information before making clinical decisions.*